nach oben

Inflammopharmacology

Erschienen in:

01.04.2013 | Commentary

Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients?

verfasst von: David A. Clark

Erschienen in: Inflammopharmacology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Concern has been raised about an increased risk of lymphoma and skin cancers in patients with rheumatoid arthritis due to administration of anti-TNF-α drugs. Meta-analysis of observational data from registries as well as from randomized controlled trials has failed to show a significant increase in the risk of lymphoma when the sample size has been sufficiently large; skin cancer risk may represent a valid concern. Issues relating to interpretation of these data are discussed.

Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltslius N, Coster L, Geborek P, Jacobsen LT, Lindblad S, Rantapaa-Dahlqvist S, Saxne T, Klareskog L (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies. Does the risk change with the time since start of treatment? Arthr Rheum 60:3180–3189CrossRef

Beacklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Irinel AI, Rosenquist R, Feltelius N, Sundstrom C, Klareskog L (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthr Rheum 54:692–701CrossRef

Clark DA (2012) The end of evidence-based medicine? Inflammopharmacology 20:187–193PubMedCrossRef

Drug Safety Committee (2012) Drug Safety Quarterly 4(2):1–4

Horton SC, Nam JL, Buch MH (2012) Safety of biologics in rheumatoid arthritis. Int J Clin Rheumatol 7:425–251 (Medscape CME, http://www.medscape.org/viewarticle/768769)

Kahneman D (2011) Thinking fast and slow. Doubleday, Canada

Lopez-Olivio MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, Fultom S, Suarez-Almazor ME (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biological therapy. JAMA 308:898–908CrossRef

Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, Heresbacj D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P (2010) Lymphoma in patients treated with anti-TNF: results of the 3 year prospective French RATIO registry. Ann Rheum Dis 69:400–408PubMedCrossRef

Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven A, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P (2011) Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895–1904PubMedCrossRef

Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzanai C, Gorla R, Marchesoni A, Favalli EG, Montecucco C (2010) Tumor necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 9:175–180PubMedCrossRef

Schwartz RS (1974) Immunosuppressive chemotherapy and malignancy. Transpl Proc 6(Suppl 1):45–48

Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook G, Schneeweiss S (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthr Rheum 54:2757–2764CrossRef

Solomon DH, Mercer E, Kavanaugh A (2012) Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis. Arthr Rheum 64:21–32CrossRef

Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy. Arthr Rheum 56:2886–2895CrossRef

Titel: Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients?
verfasst von: David A. Clark
Publikationsdatum: 01.04.2013
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammopharmacology / Ausgabe 2/2013
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-012-0158-0

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients?

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Antihypernociceptive activity of anethole in experimental inflammatory pain

Immunosuppressive effects of Euphorbia hirta in experimental animals

Lyme disease: aetiopathogenesis, factors for disease development and control

25-Hydroxy vitamin D3 modulates dendritic cell phenotype and function in Crohn’s disease

Garlic (Allium sativum) down-regulates the expression of angiotensin II AT1 receptor in adrenal and renal tissues of streptozotocin-induced diabetic rats

Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats